Mental health is on the decline all over the world.
At the moment, nearly 264 million people are struggling with depression, for example. To help alleviate the symptoms of depression, many turn to anti-depressants such as SSRIs (selective serotonin reuptake inhibitors). Problem is — SSRIs aren’t always useful, focusing more on symptom suppression than root cause.
Of course, that needs to change.
That being said, the pharmaceutical industry is overdue for a massive, game-changing revolution when it comes to mental health care.
Fortunately, the revolution has already begun with the study of psilocybin. That could be beneficial for related companies such as MYND Life Sciences Inc. (CSE:MYND), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), MindMed (NASDAQ:MNMD)(NEO:NMED), Compass Pathways (NASDAQ:CMPS), and Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF).
Better, a new study by Yale “supports the findings of previous laboratory experiments that indicate psilocybin and the aesthetic ketamine – both popular recreational drugs – can decrease depression,” as reported by Yale University.